Rocky Mountain Advanced Genome (v. 1.3) Harvard Case Solution & Analysis

In January 1996, the investment manager of hedge fund is considering buying a stake in the start-up biotechnology company, Rocky Mountain Advanced Genome (RMAG). The asking price is $ 46 million for a 90% stake. Although the leaders of the company are optimistic about their future activities, the investment manager is more conservative in their expectations. She asks analyst fashion counterproposal to control RMAG in. Problems for students to apply the concept of the ultimate cost, completed tests and interpret data, and to receive the consequences of various terminal value assumptions to recommend a counteroffer. Small computing requires students.
This Darden study. "Hide
by Robert F. Bruner Source: Darden School of Business 20 pages. Publication Date: April 3, 1996. Prod. #: UV0005-PDF-ENG

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.